The expulsion of Echinostoma trivolvis caused by goblet cell hyperplasia in severe combined immunodeficient (SCID) mice.
Mice with severe combined immunodeficiency (SCID), lacking functional T and B lymphocytes, were each infected with 40 Echinostoma trivolvis metacercarial cysts on day 0. The mice of the test group were given intramuscular injections of dexamethasone (DEX) daily for 2 weeks and necropsied on days 5, 8, 12, 15, 20 and 30 post-infection (p. i.). The control mice, not treated with DEX, were each infected with 40 echinostome cysts on day 0 and necropsied on the same days as the DEX-treated mice. In the control mice, worm rejection began about day 8 p. i. and the worms were completely rejected by day 15 p. i., corresponding to the peak in goblet cell hyperplasia, about day 12 p. i. In the DEX-treated mice, goblet cell hyperplasia was significantly suppressed and the worms were retained until day 15 p. i., and then rejected after the last treatment with DEX. The number of mucosal mast cells, that increased with worm infection and peaked about day 15 p. i., was apparently suppressed by treatment with DEX. The eosinophil number in the controls increased on day 15 p.i. approximately and then decreased. The eosinophil number in the DEX-treated mice increased as in the controls, but was significantly suppressed compared to that of the controls during the period of the experiment. Enzyme-linked immunosorbent assay (ELISA) showed no marked rise in titres of the sera IgM, IgA and IgG throughout the experiment in both groups. These results indicate that DEX-treatment delayed the rejection of E. trivolvis from the small intestine of SCID mice in association with the suppression of goblet cell hyperplasia. It is concluded that the host immune system is not involved in the rejection of E. trivolvis and the effector cells for worm rejection are goblet cells that markedly increase in numbers by infection with E. trivolvis.
Fujino
T
T
Department of Biology, Faculty of Science, Yamagata University, Japan.
Ichikawa
H
H
Fukuda
K
K
Fried
B
B
D000818:Animals; D000909:Antibodies, Helminth / Q000097:blood; D002432:Cecum / Q000469:parasitology; D002452:Cell Count; D003106:Colon / Q000469:parasitology; D003907:Dexamethasone / Q000494:pharmacology* / Q000627:therapeutic use; D004449:Echinostoma / Q000187:drug effects / Q000276:immunology*; D004451:Echinostomiasis / Q000188:drug therapy / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000473:pathology; D005938:Glucocorticoids / Q000494:pharmacology* / Q000627:therapeutic use; D020397:Goblet Cells / Q000187:drug effects / Q000473:pathology*; D006965:Hyperplasia; D007136:Immunoglobulins / Q000097:blood; D007421:Intestine, Small / Q000469:parasitology; D008297:Male; D008407:Mast Cells / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D012007:Rectum / Q000469:parasitology
D000909:Antibodies, Helminth; D005938:Glucocorticoids; D007136:Immunoglobulins; D003907:Dexamethasone